Understanding Preferences for Anticoagulation in Atrial Fibrillation
Author Information
Author(s): Pablo Alonso-Coello, Victor M. Montori, Ivan Solà, Holger J. Schünemann, Philip J. Devereaux, Cathy Charles, Mercè Roura, M. Gloria Díaz, Juan Carlos Souto, Rafael Alonso, Sven Oliver, Rafael Ruiz, Blanca Coll-Vinent, Ana Isabel Diez, Ignasi Gich, Gordon Guyatt
Primary Institution: Iberoamerican Cochrane Center, Hospital Sant Pau, Barcelona, Spain
Hypothesis
Do patients' and clinicians' preferences explain the utilization of warfarin to prevent strokes associated with atrial fibrillation?
Conclusion
The study aims to explore the differences in treatment preferences between patients and clinicians regarding anticoagulation therapy for atrial fibrillation.
Supporting Evidence
- Less than 40% of patients with atrial fibrillation receive warfarin.
- Patients are generally more stroke-averse than bleeding-averse.
- Clinicians may perceive patients as being at high risk of bleeding, affecting their treatment recommendations.
Takeaway
This study is trying to find out why some patients with atrial fibrillation don't get the blood thinner warfarin, even though it can help prevent strokes.
Methodology
The study will conduct structured interviews and focus groups to assess treatment preferences for warfarin vs. aspirin among patients and clinicians.
Potential Biases
Clinicians may have a bias towards avoiding bleeding risks more than patients do.
Limitations
The previous study lacked detailed presentations of warfarin use and did not consider all causes of death related to bleeding and strokes.
Participant Demographics
Patients aged 60 and older with conditions like diabetes and hypertension; clinicians from various specialties.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website